DUBLIN--(BUSINESS WIRE)--The "Dental Soft Tissue Regeneration Market Report Suite | Europe | 2020-2026 | MedCore" report has been added to ResearchAndMarkets.com's offering.
The EU dental soft tissue regeneration market was valued at €7.3 million in 2019. The market value is expected to increase and reach somewhere in between €8.5 and €9.9 million by 2026, depending on the impact of COVID19 on the overall market.
The vast majority of unit sales were xenograft products produced by Geistlich and Botiss, and the remainder consisted mostly of AlloDerm, which is distributed by BioHorizons. Even if regulations surrounding the use of human tissue for soft tissue regeneration impede sales of these types of products throughout Europe, within the dental indication specifically, the regulatory hurdles are slightly less pronounced.
Some dentists in this market are using these devices to increase biotype and soft tissue thickness around implants. The number of dental regenerative matrix units sold is partly correlated with the number of dental implant procedures in a given country. This explains why, population differences aside, unit sales in Germany and Italy were slightly higher than in France, and significantly higher than in the United Kingdom.
Key Topics Covered:
LIST OF FIGURES
LIST OF CHARTS
PROCEDURE NUMBERS
IMPACT OF COVID-19 ON THE EUROPE DENTAL SOFT TISSUE REGENERATION MARKET
Introduction
Multi-Scenario Analysis
EUROPE DENTAL SOFT TISSUE REGENERATION MARKET
- Introduction
- Market Analysis And Forecast
- Driver And Limiters
COMPETITIVE MARKET SHARE ANALYSIS
- Botiss Biomaterials
- Geistlich
- Allergan
- Orthocell
- Zimmer Biomet
For more information about this report visit https://www.researchandmarkets.com/r/14xb50
